文献速递其他结缔组织病

JAK抑制剂对部分幼年皮肌炎患者有效:一项单中心回顾性研究

JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该单中心回顾性研究纳入10例幼年皮肌炎(JDM)患者(9例难治性、1例新发),接受芦可替尼(n=7)或巴瑞替尼(n=3)治疗并随访至少6个月。结果显示5/10患者在JAK抑制剂启用6个月内达到临床非活动性疾病(CID),所有应答者可停用血浆置换、免疫吸附及其他免疫抑制剂,平均每日激素剂量从1.1 mg/kg降至0.1 mg/kg(P=0.008),但带状疱疹感染率较高。

要点

  • JAK抑制剂可使部分难治性或新发JDM患者在6个月内达到CID。
  • 应答者可停用血浆置换、免疫吸附及其他免疫抑制剂并显著减少激素用量。
  • 总体耐受性良好,但带状疱疹感染发生率较高。

核心结论

  • JAK抑制剂可使部分新发或难治性JDM患者达到临床非活动性疾病,并可能显著逆转严重肌肉血管病变。

研究设计与样本

  • 单中心回顾性研究,纳入10例JDM患者(9例难治性、1例新发),接受芦可替尼(n=7)或巴瑞替尼(n=3)治疗,随访至少6个月。

主要发现

  • 10例中5例在JAK抑制剂启用6个月内达到CID(抗MDA5阳性2/2、抗NXP2阳性3/4、抗TIF1γ阳性0/3)。
  • 所有应答者可停用血浆置换、免疫吸附及其他免疫抑制剂。
  • 达到CID的患者平均每日激素剂量从1.1 mg/kg(范围0.35-2 mg/kg/d)降至0.1 mg/kg(范围0-0.3,P=0.008),其中2例停用激素。
  • 所有患者治疗开始时血清IFN-α浓度均升高,应答者和非应答者均恢复正常。
  • 1例患者JAK抑制剂启用26个月后重复肌肉活检显示肌内膜微血管床完全恢复。

关键数值与推荐

  • 临床非活动性疾病(CID)采用PRINTO标准和皮肤疾病活动评分评估。
  • 血清IFN-α浓度采用Simoa法检测。

临床怎么用

  • 对于难治性或新发JDM患者,JAK抑制剂可作为治疗选择之一,有助于实现CID并减少激素及免疫抑制剂用量。
  • 治疗期间需警惕带状疱疹感染。

局限性

  • 单中心回顾性研究,样本量小(10例),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of Janus kinase inhibitors (JAKis) in JDM. METHODS: We conducted a single-centre retrospective study of patients with JDM treated by JAKi with a follow-up of at least 6 months. Proportion of clinically inactive disease (CID) within 6 months of JAKi initiation was evaluated using PRINTO criteria and skin Disease Activity Score. Serum IFN-α concentration was measured by Simoa assay. RESULTS: Nine refractory and one new-onset patients with JDM treated with ruxolitinib (n = 7) or baricitinib (n = 3) were included. The main indications for treatment were refractory muscle involvement (n = 8) and ulcerative skin disease (n = 2). CID was achieved in 5/10 patients (two/two anti-MDA5, three/four anti-NXP2, zero/three anti-TIF1γ-positive patients) within 6 months of JAKi introduction. All responders could withdraw plasmatic exchange, immunoadsorption and other immunosuppressive drugs. The mean daily steroid dose decreased from 1.1 mg/kg (range 0.35-2 mg/kg/d) to 0.1 (range, 0-0.3, P = 0.008) in patients achieving CID, and was stopped in two. Serum IFN-α concentrations were elevated in all patients at the time of treatment initiation and normalized in both responder and non-responder. A muscle biopsy repeated in one patient 26 months after the initiation of JAKi, showed a complete restoration of muscle endomysial microvascular bed. Herpes zoster and skin abscesses developed in three and two patients, respectively. CONCLUSION: JAKis resulted in a CID in a subset of new-onset or refractory patients with JDM and may dramatically reverse severe muscle vasculopathy. Overall tolerance was good except for a high rate of herpes zoster infection.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Le Voyer T, Gitiaux C, Authier FJ, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford). 2021. PMID: 33576769. doi:10.1093/rheumatology/keab116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。